Daré Bioscience Ovaprene® Phase 3 Trial Shows Positive Results

Daré Bioscience is focused on addressing unmet needs in women’s health through innovative solutions. Ovaprene® represents a potential first-in-category hormone-free monthly intravaginal contraceptive. The ongoing Phase 3 trial is a multicenter, single-arm, open-label study enrolling women aged 18–40 across 5 sites (clinicaltrials.gov: NCT06127199?ref=yanuki.com). Interim results showed that approximately 9% of women in the study experienced a pregnancy, aligning with expectations based on previous studies. Participants who completed the study indicated they would likely use Ovaprene if it became available. The company also received a $6 million grant installment supporting its smart drug delivery device, highlighting the potential for broader applications beyond contraception. Shares of Daré Bioscience surged following the announcement of these positive results.

Ovaprene® is an investigational monthly, hormone-free intravaginal contraceptive being developed by Daré Bioscience.

The interim analysis showed a pregnancy rate consistent with company expectations, no new safety concerns, and favorable tolerability.

Millions of women in the U.S. are seeking effective, hormone-free birth control, suggesting a significant unmet need that Ovaprene could address.

The grant supports the development of Daré Bioscience’s smart drug delivery device, which has potential applications in contraception, obesity, and metabolic disorders.

Do you think hormone-free contraceptives like Ovaprene® will become more popular? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!